Znalezionych wyników: 2

Cytat:

Czym rozni sie pojecie carcimona invasium od ductae carcimona invasium.

Beta,

Jezeli carcinoma jest invasivum to znaczy, ze nie jest juz in situ, czyli np nie jest juz D(uctal)C(arcinoma)I(n)S(itu) lub L(obular)CIS. .
Forma inwazyjna generalnie zagraza zyciu.

Tu ilustracja:
http://www.partnershipfor...y/invasive.aspx

O estragizolu (? na pewno taka nazwa?) nie slyszalam.

Beta, mysle, ze byloby lepiej gdybys opisala tutaj z detalami cala historie choroby - badania, wyniki, zastosowane leczenie.
pzdr
zosia

Witaj Beta,

Marker CA 15-3 o poziomie przedoperacyjnym >30 units/L uwazany jest za zly progostyk jezeli chodzi o OS (czas przezycia) kobiet z rakiem piersi. Niezaleznie od statusu hormonalnego, wieku, przerzutow(lub nie ) do wezlow chlonnych. Niezaleznie od zastosowanej terapii (adjuwantowej hormonoterapii, chemioterapii czy tez radioterapii).

Badania byly robione na probie 600 pacjentek na przestrzeni ponad 6 lat.

Wprawdzie piszesz, ze testu przed operacja nie wykonano ale skoro po operacji i po chemioterapii > 30 to znaczy, ze przedtem byl tez taki byl :-(

http://www.clinchem.org/c...ull/50/3/559#T3

Abstract

Cytat:

Background: CA 15-3 is the most widely used serum marker in breast cancer. Currently, its main uses are in the surveillance of patients with diagnosed disease and monitoring the treatment of patients with advanced disease.

Methods: Preoperative CA 15-3 concentrations were measured prospectively in 600 patients with histologically confirmed breast cancer. Marker concentrations were related to patient outcome by both univariate and multivariate analysis.

Results: After a median follow-up of 6.27 years, patients with high preoperative concentrations of CA 15-3 (>30 units/L) had a significantly shorter overall survival pattern than those with low concentrations. As a prognostic factor, CA 15-3 was independent of tumor size, axillary node status, and patient age. As well as being prognostic in the total population of patients, CA 15-3 also predicted outcome in different subgroups of patients, including those with both node-negative and node-positive disease, those who were both estrogen receptor (ER)-negative and ER-positive, and those younger and older that 50 years of age. CA 15-3 was also predictive of outcome irrespective of the type of adjuvant therapy administered, i.e., whether adjuvant hormone therapy, adjuvant chemotherapy, or radiotherapy was administered.

Conclusion: Assay of CA 15-3 is a relatively inexpensive, convenient, and noninvasive method for evaluating prognosis in newly diagnosed breast cancer patients.

Pozdrawiam serdecznie,
zosia